



# GUJARAT THEMIS BIOSYN LIMITED

**CIN: L24230GJ1981PLC004878**

REGD. OFFICE & FACTORY : 69/C GIDC INDUSTRIAL ESTATE,  
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL : 0260-2430027 / 2400639

E-mail: [hrm@gtbl.in.net](mailto:hrm@gtbl.in.net)

**GTBL: CS: BSE-CORR/2023-24**

**28<sup>th</sup> December, 2023**

**The Manager,**  
Corporate Relationship Department,  
**BSE Limited,**  
Floor 25, Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001.  
Scrip Code – 506879

Dear Sir / Madam,

**Sub: Disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Please find enclosed disclosures in terms of Regulation 29 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as received from one of the Promoters, Pharmaceutical Business Group (India) Limited (PBG) intimating sale of shares of the Company.

The intimation of sale of shares as specified in this disclosure has been received by the Company from PBG on 28<sup>th</sup> December, 2023.

This is for your information and records.

Kindly acknowledge receipt.

**For Gujarat Themis Biosyn Limited**

**Rahul Soni**  
**Company Secretary and Compliance Officer**

Encl.: As mentioned above

# PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED

CIN: U24239MH1991PLC059995

Registered Office: 11/12 Udyog Nagar, S.V. Road, Goregaon West, Mumbai 400 104.

Tel: 022- 67607080 E-mail- [pbgil.250191@gmail.com](mailto:pbgil.250191@gmail.com) / [gtblmumbai@gtbl.in](mailto:gtblmumbai@gtbl.in)

---

28<sup>th</sup> December, 2023

**The Manager**  
**Listing Department**  
**BSE Limited,**  
P. J. Towers, Dalal Street  
Mumbai-400001

Dear Sir/Madam,

**Sub: Disclosures under Regulation 29 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

In terms of the provision of Regulations 29 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we being a Promoter of Gujarat Themis Biosyn Limited hereby furnish details of sale of shares of Gujarat Themis Biosyn Limited held by us as per the prescribed format enclosed herewith.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Pharmaceuticals Business Group (India) Limited**

JAYSHREE  
DINESH  
PATEL

Digitally signed by  
JAYSHREE DINESH  
PATEL  
Date: 2023.12.28  
19:33:15 +05'30'

**Jayshree Patel**

**Director**

Encl: a/a

CC:

The Company Secretary  
**Gujarat Themis Biosyn Limited**

**FORMAT FOR DISCLOSURES UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011**

Name of the Target Company (TC)	<b>GUJARAT THEMIS BIOSYN LIMITED</b>		
Name(s) of the acquirer <del>SELLER</del> and Persons Acting in Concert (PAC) with the acquirer	<b>PHARMACEUTICAL BUSINESS GROUP [INDIA] LTD</b>		
Whether the <del>acquirer</del> <b>SELLER</b> belongs to Promoter / Promoter group	<b>YES</b>		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	<b>BSE LIMITED</b>		
Details of the acquisition-/ disposal as follows	Number	% w. r. t. total share/voting capital wherever applicable (*)	% w. r. t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition DISPOSAL under consideration, holding of :</b>			
a) Shares carrying voting rights	<b>3,54,60,000<sup>A</sup></b>	<b>48.81%</b>	<b>48.81%</b>
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others)	<b>17,00,000<sup>A</sup></b>	<b>2.34%</b>	<b>2.34%</b>
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			
e) Total (a+b+c+d)	<b>3,71,60,000<sup>A</sup></b>	<b>51.15%</b>	<b>51.15%</b>
<b>Details of acquisition/sale</b>			
a) Shares carrying voting rights <del>acquired</del> /sold	30,00,000	4.13%	4.13%
b) VRs acquired /sold otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) <del>acquired</del> /sold			
d) Shares encumbered / invoked/released by the acquirer			
e) Total (a+b+c+/-d)	<b>30,00,000</b>	<b>4.13%</b>	<b>4.13%</b>

<b>After the acquisition/sale, holding of:</b>			
a) Shares carrying voting rights	3,41,60,000	47.02%	47.02%
b) Shares encumbered with the acquirer			
c) VRs otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
e) Total (a+b+c+d)	<b>3,41,60,000</b>	<b>47.02%</b>	<b>47.02%</b>
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	<b>BLOCK SALE</b>		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	<b>27<sup>TH</sup> DECEMBER, 2023</b>		
Equity share capital / total voting capital of the TC before the said acquisition / sale	<b>NO. OF SHARES: 7,26,43,510<sup>#</sup> VALUE OF SHARES: 7,26,43,510 (FV OF Rs. 1/-)</b>		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	<b>NO. OF SHARES: 7,26,43,510<sup>#</sup> VALUE OF SHARES: 7,26,43,510 (FV OF Rs. 1/-)</b>		
Total diluted share/voting capital of the TC after the said acquisition / sale	<b>NO. OF SHARES: 7,26,43,510<sup>#</sup> VALUE OF SHARES: 7,26,43,510 (FV OF Rs. 1/-)</b>		

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(<sup>^</sup>) Pursuant to Sub-Division (Stock Split) of equity shares of the Company from the Face Value of Rs. 5/- to Face Value of Rs. 1/- per share, the number of shares held by the Promoter, Pharmaceuticals Business Group of (India) Limited (PBG) has been increased to **3,71,60,000** from existing **74,32,000** after the Record Date i.e. 10<sup>th</sup> October, 2023. Also, PBG has recently pledged its **17,00,000** equity shares held in the TC in favour Bajaj Finance Ltd. for providing security for the loan being taken. We understand that above details shall be reflected in the Shareholding Pattern to be submitted by the Company for the quarter ended 31<sup>st</sup> December, 2023.

(#) As per Shareholding pattern submitted the exchange for the quarter ended 30-Sept-2023, total no. of shares held by promoter(s) and Public shareholders was **1,45,28,702**. However, as stated above, due to Sub-Division (Stock Split) of equity shares of the Company from the Face Value of Rs. 5/- to Face Value of Rs. 1/- per share and after the Record Date, aggregate number of shares of the Company has been increased to **7,26,43,510** from **1,45,28,702**. We understand that after this sale of shares by PBG, there will be no change in the share capital structure of the TC.

**JAYSHREE**  
**DINESH**  
**PATEL**

Digitally signed by  
JAYSHREE DINESH  
PATEL  
Date: 2023.12.28  
19:33:49 +05'30'

**Signature of the acquirer/ seller / Authorised Signatory**

Place:

Date: